Cargando…
Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance
PURPOSE: Approximately 15% to 20% of our patients with head and neck cancer receiving neoadjuvant chemotherapy (NACT) discontinue therapy because of various nonmedical reasons. We sought to analyze the factors associated with treatment default and noncompliance among these patients. PATIENTS AND MET...
Autores principales: | Patil, Vijay M., Noronha, Vanita, Joshi, Amit, Muddu, Vamshi, Dhumal, Sachin, Bhattacharjee, Atanu, Prabhash, Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539870/ https://www.ncbi.nlm.nih.gov/pubmed/28804775 http://dx.doi.org/10.1200/JGO.2015.000265 |
Ejemplares similares
-
Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019) -
Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers
por: Patil, Vijay M., et al.
Publicado: (2015) -
Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Patil, Vijay M, et al.
Publicado: (2014) -
Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation)
por: Patil, Vijay M., et al.
Publicado: (2016) -
A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)